Search

Introduction Infertility is a major source of life stress and could be associated with male sexual dysfunction. We investigated sexual function in male partner of infertile couples during timed intercourse (TI) and the usage of PDE5-inhibitor for ED treatment Materials and methods Male partners of couples with more than 1 year of infertility period seeking medical care or an evaluation of couple infertility were enrolled. In conjunction with infertility evaluation, the participants completed the International Index of Erectile Function (IIEF)-5 questionnaire for evaluation of sexual function. The patients were also asked about the usage of phosphodiesterase type 5 inhibitor (PDE5-I) such as sildenafil or tadalafil for erectile dysfunction (ED) treatment. Patients with azoospermia, hypogonadism, underlying chronic medical disease, previous exposure to gonadotroxin were excluded. Results A total of 236 male partners were finally included. All patients had a comprehensive interview, physical examination, semen analysis, and/or hormonal profile study. The mean age of the patients was 38.5 years (range, 34-43 years) and mean infertile period was 18±7.1 months. The incidence of mild to moderate ED (IIEF-5 score, ≤16) in men of infertile couple was 8.9% (21/236) and the incidence of mild ED (IIEF-5 score, 17-21) was 42% (99/236). However, only 5.8% (12/236) have used PDE5-I for ED treatment during fertile period. Conclusions Sexual dysfunction is common in male partners of infertile couple. Medical personnel dealing with infertile couple should consider active counselling and treatment for male partner’s sexual dysfunction.

Introduction As testosterone replacement therapy (TRT) use increases, its role on cardiovascular health must be explored. However, the effect of testosterone in cardiovascular health remains unclear. We evaluated the lipid profile changes with TRT in the population with testosterone deficiency syndrome. Material and methods We performed a retrospective observational study in 230 male patients (mean age 60.1 years) with testosterone deficiency syndrome between 2007 and 2012 at the Asan Medical Center. Testosterone was replaced in hypogonadal patients by regular intramuscular injection (long acting testosterone undecanoate, 1,000 mg) every 3 month at least for 1 year. The parameters estimated at the time of diagnosis, 6 and 12 months after TRT were: total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C). Results Total cholesterol was significantly decreased after 6 months by TRT compared to before TRT (183.7±33.9, 175.5±33.1, P=0.001). Triglycerides was also significantly decreased after 6 months (147.2±84.1, 131.2±62.7, P=0.009). TC and TGs were decreased after 12 months. However, there were no changes in LDL-C at 6 months (114.2±27.7, 110.2±30.1, P=0.44) and 12 months (114.2±27.7, 110.8±25.7, P=0.159) after TRT. The change was not found in HDL-C at 6 and 12 months (50.2±13.7, 50.1±14.6, 49.5±13.9). There was no increase in PSA with treatment at 6 months, however the increase was found at 12 months (0.85±0.58, 1.17±1.2, P=0.002). Conclusions TRT has the efficacy to reduce total cholesterol and triglycerides. But LDL-C and HDL-C were not changed at 6 and 12 months after TRT.